TickerWorth Open the interactive view →

Jazz Pharmaceuticals plc (JAZZ) — Available-Data Snapshot

Updated Nov 10, 2026 · available-data snapshot · descriptive, not a DCF, not advice

Price
$243.54
Market cap
$15,632,922,624
52-week high
$266.38
52-week low
$132.10
Currency
USD
Exchange
NasdaqGS

We don't publish a discounted-cash-flow fair value for Jazz Pharmaceuticals plc (JAZZ) because the free data sources we rely on don't expose the multi-year financials a DCF needs — common for small or thinly-covered listings. Rather than invent numbers, this page shows an honest snapshot of what the public data does support: the current price and size, any relative valuation multiples that exist, a book-value view, and a price-based read. Treat it as a descriptive starting point, not a valuation and not investment advice.

On the numbers we do have, JAZZ trades at a recent price of $243.54, a market capitalisation of about $15,632,922,624, sitting 83% of the way up its 52-week range ($132.10–$266.38), on the NasdaqGS.

The standard alternative to a DCF is relative valuation — comparing JAZZ's trading multiples against a sector benchmark. Here that gives P/E of 72.1× (richer than the peer median of 45.8×); Fwd P/E of 9.4× (cheaper than the peer median of 18.1×); P/B of 3.7× (cheaper than the peer median of 8.3×); P/S of 3.3× (cheaper than the peer median of 6.8×); EV/EBITDA of 9.2× (cheaper than the peer median of 18.5×). A cheaper multiple than peers can flag a discount or a market that expects weaker growth; it is a comparison, not a recommendation.

The asset, or book-value, lens is the classic tool for asset-heavy businesses and financials. JAZZ shows a price-to-book (P/B) of 3.72 and book value of $65.39 per share. Price-to-book compares the market price to the accounting net-asset value per share; below 1.0 can mean a discount to net assets or that the market is pricing in trouble — descriptive either way, never a buy signal on its own.

Finally, a price-based read — explicitly not a valuation. JAZZ is in an up-trend (price above both its 50- and 200-day averages), trading -8.6% from its 52-week high. Over the past year the stock is +76.3%. Moving-average trend and 52-week position describe where the stock has traded; they say nothing about what it is worth.

Relative valuation — JAZZ vs peers

MultipleJAZZPeer median
P/E72.1×45.8×richer than
Fwd P/E9.4×18.1×cheaper than
P/B3.7×8.3×cheaper than
P/S3.3×6.8×cheaper than
EV/EBITDA9.2×18.5×cheaper than

Sector benchmark (bellwethers, not direct competitors).

Asset / book-value view

Price / book (P/B)
3.72
Book value / share
$65.39

Price-to-book compares the market price to the accounting net-asset value per share. Most useful for asset-heavy businesses, banks and insurers.

Price-based snapshot

50-day avg
$229.39
200-day avg
$218.09
From 52-wk high
-8.6%
1-year momentum
+76.3%

Price-based, not a valuation. Moving-average trend and 52-week position describe where the stock has traded — they say nothing about fair value.

Explore more

Most undervalued stocks (per our valuation) · All valued stocks · Interactive JAZZ view

A descriptive, available-data snapshot and relative comparison — NOT a DCF, NOT a price target, and NOT investment advice. TickerWorth is an educational tool, not a licensed investment adviser. Figures are estimates derived from public market data and can be wrong, stale or incomplete.